Open AccessIndividual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma
Author(s) -
Б. Я. Алексеев,
И. М. Шевчук,
А. Д. Каприн
Publication year - 2018
Publication title -
onkourologiâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 4
eISSN - 1996-1812
pISSN - 1726-9776
DOI - 10.17650/1726-9776-2018-14-2-68-78
Subject(s) - medicine , sunitinib , axitinib , renal cell carcinoma , oncology , regimen , targeted therapy , disease , cancer
Renal cell carcinoma (RCC) is one of the most common genitourinary malignancies worldwide. Approximately 25–30 % of newly diagnosed patients have metastatic RCC (mRCC), whereas in 20–30 % of cases, dissemination occurs after radical surgical treatment. The development of targeted and immunooncological agents in recent years significantly increased survival in patients with mRCC. However, clinicians faced a problem of choosing an optimal therapeutic regimen to achieve maximum effectiveness of the treatment. This article discusses the choice of second-line drugs for mRCC, advantages of axitinib and its optimal dosage, and efficacy of sunitinib depending on the disease prognosis.